Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy

**Background:** Two thirds (62%) of metastatic breast cancer (MBC) patients in Western Europe have human epidermal growth factor receptor 2 (HER2)-negative disease, for which anthracyclines and taxanes are recommended as first-line treatments, followed by microtubule-targeting agents such as capecit...

Full description

Saved in:
Bibliographic Details
Main Authors: Gabriel Tremblay, Unnati Majethia, Ilias Kontoudis, Jesús De Rosendo
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2015-10-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/9834
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items